| Subtype | % of Cases | Median Age | 5-Yr Survival | Hormone Status | Common Treatments | Notes |
|---|---|---|---|---|---|---|
| HR+/HER2- (Luminal A) | 68% | 64 yrs | 92% | ER+ and/or PR+, HER2- | Hormone therapy (tamoxifen, AIs) | Slow-growing, best prognosis |
| HR+/HER2+ (Luminal B) | 18% | 59 yrs | 88% | ER+ and/or PR+, HER2+ | Hormone therapy + anti-HER2 (trastuzumab) | More aggressive than Luminal A |
| HER2+ (non-luminal) | 8% | 55 yrs | 82% | ER-/PR-, HER2+ | Chemo + anti-HER2 (pertuzumab, T-DM1) | Targeted therapies improve survival |
| Triple-Negative (TNBC) | 12% | 52 yrs | 65% | ER-/PR-/HER2- | Chemotherapy (immunotherapy for PD-L1+) | Most aggressive, higher risk in Black women |
| Subtype | White Women | Black Women | Asian Women | Hispanic Women |
|---|---|---|---|---|
| HR+/HER2- | 70% | 58% | 72% | 65% |
| Triple-Negative | 10% | 25% | 12% | 15% |
| HER2+ | 17% | 16% | 15% | 19% |
Key Insight: Black women have 2.5x higher TNBC rates and worse survival (55% vs. 68% in Whites).
| Subtype | Stage I (%) | Stage II (%) | Stage III (%) | Stage IV (%) |
|---|---|---|---|---|
| HR+/HER2- | 100 | 93 | 72 | 29 |
| HR+/HER2+ | 98 | 90 | 68 | 25 |
| HER2+ (non-luminal) | 95 | 83 | 55 | 18 |
| Triple-Negative | 91 | 65 | 40 | 9 |
Note: TNBC's poor survival stems from lack of targeted therapies and rapid metastasis.
Sources: American Cancer Society (2024), SEER Program, NCCN Guidelines v3.2024
